Literature DB >> 30217300

Long-term outcomes of laparoscopic versus open D2 gastrectomy for advanced gastric cancer.

Zhengyan Li1, Bofei Li2, Bin Bai2, Pengfei Yu2, Bo Lian2, Qingchuan Zhao3.   

Abstract

BACKGROUND: Technical safety and short-term surgical outcomes of laparoscopy-assisted gastrectomy (LAG) for advanced gastric cancer (AGC) have been investigated in many clinical trials. However, studies with large sample size and sufficient follow-up comparing LAG and open gastrectomy (OG) for AGC have seldom been reported. The purpose of this study was to compare the long-term outcomes of LAG versus open OG for AGC using a propensity score matching analysis.
METHODS: We retrospectively evaluated 459 and 856 patients who underwent LG or OG with D2 lymph node dissection, respectively, for AGC between June 2007 and June 2012. One-to-one propensity score matching was performed to compensate for heterogeneity between groups. We compared long-term outcomes between the two groups after propensity score matching.
RESULTS: In the propensity score-matched cohort, no significant differences were observed in 5-year overall survival (OS) (52.0% vs. 53.4%; P = 0.805) and disease-free survival (DFS) (46.8% vs. 47.3%; P = 0.963) between the LAG group and OG group. Stratified analysis showed that the 5-year OS and DFS rates were comparable between the two groups in each tumor stage (P > 0.05). Multivariate analysis revealed that the operation method was not an independent prognostic factor for OS or DFS. Further analysis showed that the recurrence pattern was similar between the LAG group the OG group (P > 0.05).
CONCLUSION: LAG is a feasible surgical procedure for AGC in terms of long-term prognosis, although the results should be confirmed by the ongoing randomized controlled trials.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Gastrectomy; Gastric cancer; Laparoscopy; Long-term outcome

Mesh:

Year:  2018        PMID: 30217300     DOI: 10.1016/j.suronc.2018.05.022

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  7 in total

1.  Laparoscopic vs Open Gastrectomy: an Updated Meta-analysis of Randomized Control Trials for Short-Term Outcomes.

Authors:  Bhavin Vasavada; Hardik Patel
Journal:  Indian J Surg Oncol       Date:  2021-08-09

2.  Comparison of long-term oncologic outcomes laparoscopy-assisted gastrectomy and open gastrectomy for gastric cancer.

Authors:  Xin-Yu Mao; Hua Zhu; Wei Wei; Xin-Lei Xu; Wei-Zhi Wang; Bao-Lin Wang
Journal:  Langenbecks Arch Surg       Date:  2020-10-06       Impact factor: 3.445

3.  A study of outcomes, technical safety, and feasibility of D-2 lymphadenectomy in gastric cancer.

Authors:  Abhijit Talukdar; Srinivas Bannoth; Joydeep Purkayastha; Bibhuti B Borthakur; Deepjyoti Kalita; Gaurav Das; Niju Pegu; Pritesh Singh
Journal:  JGH Open       Date:  2020-08-08

4.  Laparoscopic gastrectomy for elderly gastric-cancer patients: comparisons with laparoscopic gastrectomy in non-elderly patients and open gastrectomy in the elderly.

Authors:  Zheng-Yan Li; Jie Chen; Bin Bai; Shuai Xu; Dan Song; Bo Lian; Ji-Peng Li; Gang Ji; Qing-Chuan Zhao
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-09-10

5.  Robotic total gastrectomy for carcinoma in the remnant stomach: a comparison with laparoscopic total gastrectomy.

Authors:  Zheng-Yan Li; Jia-Jia Liu; Pei-Wu Yu; Yong-Liang Zhao; Yan Shi; Zi-Yan Luo; Bin Wu; Jun-Jie Wang; Feng Qian
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-07-19

Review 6.  Long-term and short-term outcomes after laparoscopic versus open surgery for advanced gastric cancer: An updated meta-analysis.

Authors:  Wei Zhang; Zhangkan Huang; Jianwei Zhang; Xu Che
Journal:  J Minim Access Surg       Date:  2021 Oct-Dec       Impact factor: 1.407

7.  Laparoscopic versus open approach in gastrectomy for advanced gastric cancer: a systematic review.

Authors:  Zhipeng Zhu; Lulu Li; Jiuhua Xu; Weipeng Ye; Junjie Zeng; Borong Chen; Zhengjie Huang
Journal:  World J Surg Oncol       Date:  2020-06-13       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.